14th October 2026

The regulations surrounding pharmaceutical serialisation in Asia have evolved into a complex maze of mandates, each shaped by distinct national priorities, market structures and legislative timelines. Collectively, these create substantial challenges to compliance for pharmaceutical manufacturers and distributors who serve multiple markets across Asia. Track and trace pharma systems are designed to enable the authentication of individual saleable units and follow their movement through the supply chain. And while this remains consistent across jurisdictions, the specific data elements, encoding standards, reporting obligations and implementation schedules vary considerably from country to country.

Asia’s adoption of GS1 standards [1] has provided a degree of harmonisation forming the backbone of serialisation frameworks in many countries. However, their implementation and interpretation still diverge across borders, and the diversity of serialisation mandates reflects varying national pharmaceutical supply chain risks, regulatory maturity and technology infrastructure. Several ASEAN member states (including China, Japan, South Korea and India) each possess distinct regulations, creating a compliance environment where pharmaceutical companies must navigate fundamentally requirements across borders

Non-compliance can cost, with companies facing penalty fines as well as products being detained at borders, which creates strong incentives to implement robust serialisation strategies. And with Asia’s pharmaceutical market set to reach a valuation of USD 700 billion by 2031, [2] traceability has never been more urgently needed, not merely for compliance but for supply chain visibility and operational efficiency.

Divergent serialisation mandates across key Asian markets

Pharmaceutical serialisation in China

Established through regulations issued by the National Medical Products Administration (NMPA), China’s framework mandates the unique serialisation of each saleable unit of pharmaceutical products, encoded in a 2D Data Matrix barcode containing specific data elements including the product code, serial number, and national drug code. As operated by the NMPA’s Center for Drug Evaluation, the Drug Traceability System requires manufacturers to upload product information, production batch details and logistics information to a central database. This creates a comprehensive traceability infrastructure that enables verification of product authenticity and tracking of product movement through distribution channels.

Pharmaceutical serialisation in India

As major pharmaceutical exporter, India’s serialisation mandates [3] are designed primarily to address the requirements of importing countries and supporting supply chain security for its pharma exports. India's approach has evolved through the Directorate General of Foreign Trade's Track and Trace system for exported pharmaceuticals, with specific requirements for tertiary-level (shipping case) serialisation and secondary-level serialisation being phased in over time. Leveraging GS1 standards for product identification, the country has employed Global Trade Item Numbers (GTINs) encoded in GS1-128 linear barcodes for tertiary packaging and GS1 Data Matrix codes for secondary packaging, with data maintained in a centralised repository operated by the government.

Pharmaceutical serialisation in South Korea

Operational since 2016, South Korea is home to one of Asia's most mature track-and-trace frameworks, with the Korea Pharmaceutical Information Service’s national database capturing information on all reimbursable prescription drugs from manufacturing through dispensing. The Korean system employs GS1-compliant 2D Data Matrix codes containing product codes, serial numbers, expiry dates and lot numbers, which manufacturers are required to report to the national database at each node in the supply chain.

Pharmaceutical serialisation in Japan

Japan's pharmaceutical serialisation framework is regulated by the Ministry of Health, Labour and Welfare, focusing initially on biologic products and high-risk medications. The system is integrated with hospital dispensing systems, allowing for verification at the point of administration. By emphasising patient safety through bedside verification rather than comprehensive supply chain tracking, the framework reflects the country's relatively low risk of counterfeiting and the advanced state of its healthcare IT infrastructure. The Japanese model illustrates how serialisation requirements can be calibrated to fit national risk profiles and healthcare system characteristics, rather than needing to follow a single uniform approach.

Aggregation challenges in complex distribution networks

As the process of establishing and maintaining parent-child relationships between packaging levels,  aggregation offers distinctive operational challenges in the context of Asia’s diverse serialisation requirements and distribution networks. Done effectively, aggregation improves the efficiency of logistics operations by allowing entire cases or pallets to be verified through scanning a single identifier rather than individual units. This also supports product recall processes by enabling identification of all affected units within aggregated containers. Some jurisdictions mandate aggregation to specific packaging levels, while others require aggregation only for exported products and some impose no aggregation requirements, allowing companies to adopt aggregation voluntarily for operational benefits.

Implementing aggregation [4] can bring about technical challenges, such as the need for reliable data association between packaging levels during production and the management of aggregation hierarchies through multiple handling steps including rework and repacking. As such, the accuracy of aggregation processes is critical, as errors in parent-child association can render entire aggregated containers unscannable or, more concerningly, create false associations that compromise traceability and recall effectiveness altogether.

The complexity of Asian pharmaceutical distribution networks, as characterised by multiple tiers of wholesalers, sub-distributors, and retailers with varying technology capabilities, amplifies these challenges, as the maintenance of aggregation hierarchies across multiple handoffs requires consistent data capture and sharing practices throughout supply chains. While distribution models in Europe and North America are relatively consolidated, Asian markets are more fragmented, with numerous intermediaries creating risks that aggregation data becomes incomplete or inaccurate as products move through distribution. Therefore, they must be able to provide initial data capture during manufacturing, as well as mechanisms for verifying and updating aggregation data as products move through distribution.

Technological solutions for multi-market compliance

These multi-step, multi-market processes for compliance require technology platforms which can manage varying data structures, barcode formats, reporting protocols and aggregation needs across jurisdictions. They also need to be adaptable enough to accommodate new markets as regulatory frameworks evolve.

Cloud-based serialisation platforms have emerged as attractive architectures for multi-market compliance, leveraging centralised infrastructure, common data models and regulatory reporting gateways. These platforms typically offer pre-configured market profiles for major jurisdictions, with regular updates maintaining compliance as regulations evolve. The cloud delivery model reduces on-premise infrastructure requirements, allowing for centralised management of serialisation operations across multiple manufacturing sites and markets.

Pharmaceutical companies must still carefully evaluate data security, system validation and business continuity considerations when adopting cloud-based serialisation solutions [5]. Validating cloud-based serialisation platforms requires risk-based approaches consistent with regulatory expectations for computerised systems used in good manufacturing practice operations. Integrating these systems with enterprise resource planning, warehouse management and distribution systems are also critical for multi-market serialisation architecture. This is because they ensure the seamless flow of serialisation data across business processes while supporting market-specific requirements for data content and format.

What’s more, line equipment such as printers, cameras, label applicators and aggregation stations must also be able to support diverse barcode formats, print qualities and line speeds. Camera-based verification systems need to be able to read and grade multiple global barcode  symbologies accurately, including GS1 Data Matrix for European and many Asian markets while maintaining verification accuracy at line speeds exceeding 300–400 units per minute.

GS1 Standards and regulatory harmonisation efforts

Bodies like the International Coalition of Medicines Regulatory Authorities and the APEC Life Sciences Innovation Forum work to reduce serialisation regulatory divergence, though progress toward comprehensive harmonisation remains gradual. The WHO's Global Surveillance and Monitoring System for substandard and falsified medical products provides a framework for international coordination [6] on pharmaceutical traceability, with member states sharing information on detected falsified products and contributing to global understanding of pharmaceutical supply chain risks. While these harmonisation efforts have not yet created uniform requirements for serialisation, they do offer platforms for regulatory convergence that may gradually reduce the complexity of multi-market serialisation compliance.

However, there are other ways for organisations to better align on serialisation and track-and-trace methodology. The upcoming Pharmapack Asia [7] event, taking place on 3-4 November 2026 at Marina Bay Sands in Singapore, brings together equipment manufacturers, labeling solution providers and serialisation software specialists to demonstrate technologies supporting pharmaceutical track-and-trace implementations across diverse markets. With an anticipated turnout of more than 2,500 attendees and 120 exhibiting companies, the show gives professionals in pharma manufacturing and packaging the chance to evaluate serialisation printing and verification equipment, aggregation systems and labeling solutions that meet the performance and compliance requirements of multiple Asian markets.

With technical specialists available to discuss application-specific challenges, and in-person demonstrations of the equipment in question, Pharmapack Asia is perfectly suited to helping organisations implement robust serialisation performance and sustained regulatory compliance across diverse markets.